Purpose: To evaluate the efficacy of boron neutron capture therapy (BNCT) for a heterotopic U87 glioblastoma model in SCID mice using boron phenylalanine (BPA), sodium borocaptate (BSH) and liposomal BSH as boron compounds at a unique, accelerator-based neutron source. Materials and methods: Glioblastoma models were obtained by subcutaneous implantation of U87 cells in the right thighs of SCID mice before administration of 350 mg/kg of BPA (BPA-group), 100 mg/kg of BSH (BSH-group) or 100 mg/kg of BSH in PEGylated liposomes (liposomal BSH-group) into the retroorbital sinus. Liposomes were prepared by reverse-phase evaporation. Neutron irradiation was carried out at a proton accelerator with a lithium target developed for BNCT at the Budker Institute of Nuclear Physics, Novosibirsk, Russian Federation. A proton beam current integral of 3 mA/hour and energy of 2.05 MeV were used for neutron generation. Results: Boron compound accumulation in tumor tissues at the beginning of irradiation was higher in the BPA group, followed by the Liposomal BSH and BSH groups. Tumor growth was significantly slower in all irradiated mice from the 7th day after BNCT compared to untreated controls (p < 0.05). Tumor growth in all treated groups showed no large variation, apart from the Irradiation only group and the BPA group on the 7th day after BNCT. The overall trend of tumor growth was clear and the differences between treatment groups became significant from the 50th day after BNCT. Tumor growth was significantly slower in the Liposomal BSH group compared to the Irradiation only group on the 50th (p = 0.012), 53rd (p = 0.005), and the 57th (p = 0.021) days after treatment. Tumor growth in the Liposomal BSH group was significantly different from that in the BPA group on the 53rd day after BNCT (p = 0.021) and in the BSH group on the 50th (p = 0.024), 53rd (p = 0.015), and 57th (p = 0.038) days after BNCT. Skin reactions in the form of erosions and ulcers in the tumor area developed in treated as well as untreated animals with further formation of fistulas and necrotic decay cavities in most irradiated mice. Conclusions: We observed a tendency of BNCT at the accelerator-based neutron source to reduce or suspend the growth of human glioblastoma in immunodeficient animals. Liposomal BSH showed better long-term results compared to BPA and non-liposomal BSH. Further modifications in liposomal boron delivery are being studied to improve treatment outcomes.
Alzheimer’s disease (AD) patients often suffer from sleep disturbances. Alterations in sleep, especially rapid eye movement sleep (REMS), can precede the onset of dementia. To accurately characterize the sleep impairments accompanying AD and their underlying mechanisms using animal models, it is crucial to use models in which brain areas are affected in a manner similar to that observed in the actual patients. Here, we focused onAppNL-G-Fmice, in which expression levels and patterns of mutated amyloid precursor protein (APP) follow the endogenous patterns. We characterized the sleep architecture of maleAppNL-G-Fhomozygous and heterozygous mice at two ages (six and 12 months). At six months, homozygous mice exhibited reduced REMS, which was further reduced at 12 months together with a slight reduction in non-REMS (NREMS). By contrast, heterozygous mice exhibited an overall normal sleep architecture. Homozygous mice also exhibited decreased electroencephalogram γ to δ power ratio during REMS from six months, resembling the electroencephalogram slowing phenomenon observed in preclinical or early stages of AD. In addition, homozygous mice showed learning and memory impairments in the trace fear conditioning (FC) at both ages, and task performance strongly correlated with REMS amount at 12 months. Finally, histologic analyses revealed that amyloid-β accumulation in the pontine tegmental area and ventral medulla followed a course similar to that of the REMS reduction. These findings support the notion that changes in REMS are an early marker of AD and provide a starting point to address the mechanism of sleep deficits in AD and the effects on cognition.
Inferring cell–cell communication networks is now a cornerstone of single-cell RNA-seq and spatial transcriptomics data analysis, relying critically on reference catalogues of experimentally supported ligand–receptor interactions. Here, we present the updated, rigorously curated connectomeDB, an open-access database of peptide-based ligand–receptor pairs comprising 3579 vertebrate interactions supported by primary experimental evidence from 2803 research articles. By critically reviewing all putative ligand–receptor pairs from connectomeDB2020, CellChatDB v2, CellPhoneDB v5, CellTalkDB, ICELLNET v2, and LIANA+, we first removed over 2900 misclassified or unsupported interactions lacking primary-literature evidence. We then expanded the resulting verified dataset through AI-assisted literature mining and manual curation, adding 827 pairs and 718 supporting articles absent from other databases, including 264 pairs first described since 2020. connectomeDB2025 contains 5429 evidence links (“triplets”), each connecting a ligand–receptor pair to a specific publication, collectively providing at least one source of primary experimental evidence for each interaction. Notably, 2359 of these triplets are exclusive to connectomeDB2025, making it the most robustly supported ligand–receptor database with primary experimental evidence. The online resource (https://connectomedb.org) provides searchable, downloadable ligand–receptor lists and detailed pair summaries, enabling accurate cell–cell communication analysis across human, mouse, and 12 other vertebrate species.